Nuclear Medicine, University of Brescia and Spedali Civili Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy.
Abdom Radiol (NY). 2018 Oct;43(10):2721-2727. doi: 10.1007/s00261-018-1542-z.
The detection rate and the metabolic behavior of 18F-FDG-PET/CT in splenic marginal zone lymphoma (SMZL) are not yet clear. Our aim was to investigate the metabolic behavior of SMZL and whether the tumor stage (acc. Ann Arbor) epidemiological (age, gender), histological (Ki-67 index, plasmacytic differentiation), and morphological (splenic diameter maximum) features might be related to 18F-FDG PET/CT results.
Fifty-one patients (34 male, 17 female; average age 70 years) with histologically confirmed SMZL who underwent a 18F-FDG PET/CT for initial staging were included: PET/CT images were analyzed visually and semi-quantitatively (SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio). Splenic uptake was divided as diffuse or focal.
Thirty-nine patients (76%) had FDG-avid SMZL (7 with focal splenic lesions and 32 with diffuse splenic uptake), while the remaining 12 had no increased splenic uptake. Among patients with FDG-avid lesions, average SUVmax was 4.3, lesion-to-liver SUVmax ratio 2.3, and lesion-to-blood pool SUVmax ratio 3. 18F-FDG avidity was significantly associated with Ki-67 index and not correlated with other features. Semiquantitative PET/CT parameters (SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio) did not correlate significantly with any variable. Progression-free survival time was not influenced by FDG avidity of SMZL.
18F-FDG avidity was noted in 76% of SMZL with diffuse splenic uptake as main pattern of presentation and is correlated with Ki-67 score only.
18F-FDG-PET/CT 在脾边缘区淋巴瘤(SMZL)中的检出率和代谢行为尚不清楚。我们的目的是研究 SMZL 的代谢行为,以及肿瘤分期(根据 Ann Arbor 分期)、流行病学(年龄、性别)、组织学(Ki-67 指数、浆细胞分化)和形态学(脾脏最大直径)特征是否与 18F-FDG PET/CT 结果相关。
51 例经组织学证实的 SMZL 患者(34 名男性,17 名女性;平均年龄 70 岁)接受了 18F-FDG PET/CT 初始分期:对 PET/CT 图像进行了视觉和半定量分析(SUVmax、病灶与肝脏 SUVmax 比值、病灶与血池 SUVmax 比值)。脾脏摄取分为弥漫性或局灶性。
39 例(76%)患者的 SMZL 摄取 18F-FDG(7 例有局灶性脾脏病变,32 例有弥漫性脾脏摄取),其余 12 例无脾脏摄取增加。在有 18F-FDG 摄取病变的患者中,平均 SUVmax 为 4.3,病灶与肝脏 SUVmax 比值为 2.3,病灶与血池 SUVmax 比值为 3.1。18F-FDG 摄取与 Ki-67 指数显著相关,与其他特征无关。半定量 PET/CT 参数(SUVmax、病灶与肝脏 SUVmax 比值、病灶与血池 SUVmax 比值)与任何变量均无显著相关性。SMZL 的 18F-FDG 摄取与无进展生存时间无关。
76%的 SMZL 表现为弥漫性脾脏摄取为主的模式,显示 18F-FDG 摄取,仅与 Ki-67 评分相关。